Angela M. Minassian

University of Oxford - The Jenner Institute

Mansfield Road

Oxford, OX1 4AU

United Kingdom

SCHOLARLY PAPERS

5

DOWNLOADS
Rank 347

SSRN RANKINGS

Top 347

in Total Papers Downloads

70,437

SSRN CITATIONS

4

CROSSREF CITATIONS

3

Scholarly Papers (5)

1.

Single Dose Administration, And The Influence Of The Timing Of The Booster Dose On Immunogenicity and Efficacy Of ChAdOx1 nCoV-19 (AZD1222) Vaccine

Number of pages: 37 Posted: 01 Feb 2021
University of Oxford - Oxford Vaccine Group, University of Siena - Institute of Global Health, University of the Witwatersrand - South African Medical Research Council Vaccines and Infectious Diseases Analytical Research Unit, Federal University of Sao Paulo, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, University of the Witwatersrand, Soweto Clinical Trials Centre, Soweto Clinical Trials Centre, University of Oxford - Centre for Vaccinology and Tropical Medicine, Setshaba Research Centre, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, Liverpool School of Tropical Medicine - Department of Clinical Sciences, University of the Witwatersrand - South African Medical Research Council Vaccines and Infectious Diseases Analytical Research Unit, University of Sheffield - Department of Infection, Immunity and Cardiovascular Disease, University of Cape Town (UCT) - Centre for Lung Infection and Immunity, University of Oxford - Jenner Institute, Newcastle upon Tyne Hospitals NHS Foundation Trust - Department of Infection and Tropical Medicine, University of Oxford - Oxford Vaccine Group, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, Wits Reproductive Health & HIV Institute (WRHI), University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University of Oxford - Oxford Vaccine Group, Liverpool School of Tropical Medicine - Department of Clinical Sciences, University of Bristol - Cellular and Molecular Medicine, University of London - St George's Vaccine Institute, University College London - Department of Infection, University of Oxford - Clinical BioManufacturing Facility, University Hospitals Birmingham NHS Foundation Trust, University of Oxford - Oxford Vaccine Group, University of the Witwatersrand - South African Medical Research Council, Liverpool School of Tropical Medicine - Department of Clinical Sciences, AstraZeneca Pharmaceuticals, University of the Witwatersrand - South African Medical Research Council, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of the Witwatersrand - South African Medical Research Council, University of the Witwatersrand - South African Medical Research Council, University Hospitals Bristol - University Hospitals Bristol and Weston NHS Foundation Trust, NIHR UCLH Clinical Research Facility, Hull University Teaching Hospitals NHS Trust, University of Oxford - Centre for Vaccinology and Tropical Medicine, AstraZeneca Pharmaceuticals, Braziland Hospital São Rafael - Escola Bahiana de Medicina e Saúde Pública, Universidade Federal do Rio Grande do Norte (UFRN), University of Oxford - The Jenner Institute, London Northwest University Healthcare, University of Oxford - Oxford Vaccine Group, University of the Witwatersrand - Perinatal HIV Research Unit, Setshaba Research Centre, University of Oxford - Oxford Vaccine Group, Hospital Quinta D'OR, University of Oxford - Oxford Vaccine Group, NIHR Imperial Clinical Research Facility, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, Hospital Universitário de Santa Maria, University of Glasgow - College of Medical, Veterinary & Life Sciences, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, Universidade Federal do Rio Grande do Sul, Western General Hospital - Clinical Infection Research Group, MRC-University of Glasgow Centre for Virus Research, University of Cambridge - Department of Medicine, Royal Papworth HospitalUniversity of Cambridge - Heart and Lung Research Institute, Nottingham University Hospitals NHS Trust, AstraZeneca Biopharmaceuticals, AstraZeneca Pharmaceuticals, AstraZeneca Pharmaceuticals, Anuerin Bevan University Health Board, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine and Independent
Downloads 51,892 (31)
Citation 3

Abstract:

Loading...

2.

Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 VOC 202012/01 (B.1.1.7)

Number of pages: 40 Posted: 04 Feb 2021
University of Oxford - Oxford Vaccine Group, University of Oxford - Big Data Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Cambridge, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Cambridge, University of Oxford - Wellcome Centre for Human Genetics, University of Oxford - The Jenner Institute, Public Health England - National Infection Service, University of Oxford - Centre for Vaccinology and Tropical Medicine, Liverpool School of Tropical Medicine - Department of Clinical Sciences, UK Biocentre, University of Sheffield - Department of Infection, Immunity and Cardiovascular Disease, University of Oxford - Oxford Vaccine Group, University of Oxford - Jenner Institute, Newcastle upon Tyne Hospitals NHS Foundation Trust - Department of Infection and Tropical Medicine, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Southampton - NIHR Southampton Clinical Research Facility and Biomedical Research Centre, Liverpool School of Tropical Medicine - Department of Clinical Sciences, University of Oxford - Oxford Vaccine Group, University of Bristol - Cellular and Molecular Medicine, University of Oxford - The Jenner Institute, University of Oxford - Jenner Institute, University of London - St George's Vaccine Institute, University College London - Department of Infection, University of Oxford - Clinical BioManufacturing Facility, University Hospitals Birmingham NHS Foundation Trust, University of Oxford - Oxford Vaccine Group, Public Health England - National Infection Service, University of London - Institute of Infection and Immunity, Queen Elizabeth University Hospital, Liverpool School of Tropical Medicine - Department of Clinical Sciences, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University Hospitals Bristol - University Hospitals Bristol and Weston NHS Foundation Trust, NIHR UCLH Clinical Research Facility, Hull University Teaching Hospitals NHS Trust, University of Cambridge, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, London Northwest University Healthcare, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, NIHR Imperial Clinical Research Facility, University of Oxford - Oxford Vaccine Group, University of Glasgow - College of Medical, Veterinary & Life Sciences, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, Western General Hospital - Clinical Infection Research Group, MRC-University of Glasgow Centre for Virus Research, Royal Papworth HospitalUniversity of Cambridge - Heart and Lung Research Institute, Nottingham University Hospitals NHS Trust, AstraZeneca Biopharmaceuticals, AstraZeneca Pharmaceuticals, Anuerin Bevan University Health Board, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Centre for Vaccinology and Tropical Medicine, Independent and Independent
Downloads 10,142 (707)
Citation 25

Abstract:

Loading...

3.

Tolerability and Immunogenicity After a Late Second Dose or a Third Dose of ChAdOx1 nCoV-19 (AZD1222)

Number of pages: 35 Posted: 28 Jun 2021
University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Oxford Vaccine Group, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, University of Oxford - Wellcome Centre for Human Genetics, University of Oxford - Oxford Vaccine Group, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, University of Oxford - Wellcome Centre for Human Genetics, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Oxford Vaccine Group, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - The Jenner Institute, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute, University of Oxford - Wellcome Centre for Human Genetics, University of Oxford - The Jenner Institute, University of Oxford - Oxford Vaccine Group, University of Oxford - Centre for Vaccinology and Tropical Medicine, University of Oxford - The Jenner Institute and Independent
Downloads 8,393 (975)
Citation 10

Abstract:

Loading...

4.

Delayed Booster Dosing Modulates Human Antigen-Specific Ig and B Cell Responses to the RH5.1/AS01 B Malaria Vaccine

Number of pages: 55 Posted: 18 Feb 2022
University of Oxford, University of Oxford, Massachusetts Institute of Technology (MIT) - Department of Biological Engineering, Harvard University - Ragon Institute of MGH, MIT and Harvard, University of Oxford, Harvard University - Ragon Institute of MGH, MIT and Harvard, University of Cambridge - Department of Engineering, University of Oxford, Ragon Institute of MGH, MIT and Harvard, National Institutes of Health (NIH) - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, University of Oxford, University of Freiburg - Institute of Experimental and Clinical Pharmacology and Toxicology, Government of the United States of America - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, University of Sheffield, University of Oxford - The Jenner Institute, University of Cambridge - Department of Engineering, Government of the United States of America - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, MassachusettsGeneral Hospital - Ragon Institute of MGH, MIT and Harvard and University of Oxford
Downloads 8 (796,809)

Abstract:

Loading...

vaccines, dosing regimen, delayed booster, systems serology, B cell probes, single cell RNA sequencing, antibody, avidity, subclass, FcRn, B cells, plasma cells, malaria

5.

Delayed Booster Dosing Improves Human Antigen-Specific IG and B Cell Responses to the RH5.1/AS01 B Malaria Vaccine

Number of pages: 50 Posted: 09 Jun 2022
University of Oxford, University of Oxford, Massachusetts Institute of Technology (MIT) - Department of Biological Engineering, Harvard University - Ragon Institute of MGH, MIT and Harvard, University of Oxford, Harvard University - Ragon Institute of MGH, MIT and Harvard, University of Cambridge - Department of Engineering, University of Oxford, Ragon Institute of MGH, MIT and Harvard, National Institutes of Health (NIH) - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, University of Oxford, University of Freiburg - Institute of Experimental and Clinical Pharmacology and Toxicology, Government of the United States of America - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, University of Sheffield, University of Oxford - The Jenner Institute, University of Cambridge - Department of Engineering, Government of the United States of America - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, MassachusettsGeneral Hospital - Ragon Institute of MGH, MIT and Harvard and University of Oxford
Downloads 2

Abstract:

Loading...

B cells, vaccines, plasma cells, antibody, systems serology, single cell RNA sequencing, BCR repertoire, vaccine booster dosing, malaria, RH5